Bain Capital Life Sciences Investors’s Aclaris Therapeutics ACRS Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,000,000	Closed	-$1.1M	–	25
2024 Q2	$1.1M	Sell	1,000,000 -2,000,000	-67%	-$2.35M	0.12%	24
2024 Q1	$3.72M	Sell	3,000,000 -500,000	-14%	-$596K	0.3%	24
2023 Q4	$3.67M	Buy	3,500,000 +100,000	+3%	+$305K	0.35%	25
2023 Q3	$23.3M	Hold	3,400,000	–	–	2.6%	11
2023 Q2	$35.3M	Hold	3,400,000	–	–	3.63%	8
2023 Q1	$27.5M	Buy	+3,400,000	New	+$43.2M	3.44%	10

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bain Capital Life Sciences Investors's ACRS Position: Q3 2024 in Review

Bain Capital Life Sciences Investors sold out of Aclaris Therapeutics (ACRS) in Q3 2024, closing a stake of 1,000,000 shares — an estimated $1.1M sold.

Bain Capital Life Sciences Investors first reported a position in ACRS in Q1 2023 and held it in 6 quarters. The position peaked at $35.3M in Q2 2023. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2024.

Bain Capital Life Sciences Investors reported no remaining Aclaris Therapeutics position as of Q3 2024 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 1,000,000 Aclaris Therapeutics shares in Q3 2024, an estimated $1.1M.
Bain Capital Life Sciences Investors first reported a position in Aclaris Therapeutics in Q1 2023 and held it in 6 quarters.
Bain Capital Life Sciences Investors's Aclaris Therapeutics position peaked at $35.3M in Q2 2023.
81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2024.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2024, filed 14 Nov 2024.